frince

About Frédéric Rince

This author has not yet filled in any details.
So far Frédéric Rince has created 543 blog entries.

Addressing treatment resistance in patients with squamous cell carcinoma of head and neck with Pr. Machiels and Blanpain

Head and neck cancer, mostly of squamous cell origin, accounts for roughly 6% of all cases of cancer, and nearly two thirds of these patients present with advanced disease (stages III and IV) which has a poor prognosis. Dr. John Bean, EORTC Medical Science Writer, recently interviewed Prof. Jean-Pascal Machiels of the Cliniques Universitaires St. Luc, Université catholique de Louvain, Brussels, and Prof.

By |2013-09-13T11:04:38+02:0013 Sep 2013|, , |0 Comments
Read More

Vaccination with GM2-KLH-QS21 does not improve outcome stage II melanomas patients in EORTC study

Results of an EORTC study published in the Journal of Clinical Oncology show that vaccination with GM2/KLH-QS-21 does not benefit patients with stage II melanoma.  Vaccination with GM2/KLH-QS-21 stimulates the production of antibodies to the GM2 ganglioside, an antigen expressed by many melanomas. Serological response to GM2 was shown to be a positive prognostic factor in patients with melanoma and was the rationale for this trial.

By |2013-09-13T10:57:58+02:0013 Sep 2013|, , |0 Comments
Read More

EORTC-Alliance-SIOG underline need for appropriate endpoints and designs for clinical trials in elderly patients with cancer

In a paper recently appearing in the Journal of Clinical Oncology, the European Organisation for Research and Treatment of Cancer (EORTC), the International Society of Geriatric Oncology (SIOG), and the Alliance for Clinical Trials in Oncology (Alliance) point out how changes in clinical trial designs are needed in order to understand how new treatments affect the elderly cancer patient population. The authors also address the advantages and disadvantages of specific clinical trial endpoints for elderly patients.

By |2013-09-13T10:29:37+02:0013 Sep 2013|, , |0 Comments
Read More

Pr. Françoise Meunier awarded ECCO Lifetime Achievement Award at ECC 2013 in Amsterdam

The ECCO Lifetime Achievement Award honors individuals who have made an outstanding contribution to the fight against cancer, by impacting the cancer field or the cancer professional community, and by demonstrating a lifetime commitment to progress against cancer.

By |2013-09-13T10:00:00+02:0013 Sep 2013|, |0 Comments
Read More

EORTC at 2013 ECCO-ESMO-ESTRO Meeting in Amsterdam

 

EORTC at 2013 ECCO-ESMO-ESTRO Meeting in Amsterdam

The EORTC will have an active presence at the 2013 ECCO-ESMO-ESTRO Meeting in Amsterdam, The Netherlands, from 27 September to 01 October 2013 and would like to call your attention to the following presentations.

By |2013-09-12T17:19:34+02:0012 Sep 2013|, |0 Comments
Read More

EORTC President Roger Stupp receives Hamilton Fairley Award at the European Cancer Congress 2013

EORTC President Roger Stupp to receive Hamilton Fairley Award at the European Cancer Congress 2013.

By |2013-09-12T13:09:00+02:0012 Sep 2013|, , |0 Comments
Read More

Breast cancer samples from the MINDACT trial stored at IBBL

IBBL (Integrated BioBank of Luxembourg) has announced that it now hosts an extensive breast cancer collection from a European clinical trial. The EU-supported study aims to improve prediction of the risk of recurrence in breast cancer patients in order to better select patients who can safely be spared chemotherapy.

By |2013-08-14T17:37:29+02:0014 Aug 2013|, , |0 Comments
Read More

Moderate dose radiotherapy effective in EORTC trial for patients with desmoid-type fibromatosis

A phase 2 EORTC trial for patients with inoperable desmoid-type fibromatosis has shown that moderate dose radiotherapy is an effective treatment for patients with such a rare type of tumor. The study results published in Annals of Oncology show that response after radiation therapy is slow, and that continuing regression is seen even after three years.

By |2013-07-18T16:35:23+02:0018 Jul 2013|, , , |0 Comments
Read More

3rd Annual Brain Metastases Research and Emerging Therapy Conference

We are pleased to welcome you to Marseille for the third Annual Brain Metastases Research and Emerging Therapy Conference. Last year’s successful edition has prompted us to once again organize this conference. Over the past several months, the EORTC has launched the development of a Brain Metastasis platform, created in August 2012, in order to optimally develop and conduct projects focusing on brain metastases.

By |2013-07-17T16:50:32+02:0017 Jul 2013|, , , |0 Comments
Read More
Go to Top